Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06471972

Biomarkers After Out-of-hospital Cardiac Arrest- a STEPCARE Substudy

A prospective multicenter biomarker study with adult patients treated on

intensive care units after out-of-hospital cardiac arrest. Patients will be recruited from specific sites participating in the Sedation, Temperature and Pressure After Cardiac Arrest and Resuscitation (STEPCARE) trial. (ClinicalTrials.gov ID NCT05564754).

Blood samples will be collected at 12, 24, 48, and 72 hours after randomization in selected sites, aliquoted and frozen on-site. After trial completion, samples will be stored in a central biobank. Sample analysis will be performed in batch after trial completion. Functional outcome will be assessed at 30 days and 6 months after cardiac arrest.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Helsinki Hospital, Helsinki, Finland

Loading trial locations.

About this study

A prospective multicenter biomarker study with adult patients treated on intensive care units after out-of-hospital cardiac arrest. Patients will be recruited from specific sites participating in the Sedation, Temperature and Pressure After Cardiac Arrest and Resuscitation (STEPCARE) trial. (ClinicalTrials.gov ID NCT05564754). The STEPCARE-trial is a 2x2x2 randomised trial studying patients who have been resuscitated from cardiac arrest and who are comatose. It will include three different interventions focusing on sedation targets, temperature targets and mean arterial pressure targets.

3500 patients who are comatose after cardiac arrest will be included in the STEPCARE trial studying three separate targets. All patients will be randomised to a control or an intervention arm for sedation, temperature and blood pressure targets as follows:

  • Continuous deep sedation for 36 hours or minimal sedation (SEDCARE)
  • Fever management with or without a feedback-controlled device (TEMPCARE)
  • A mean arterial pressure target of >85mmHg or >65mmHg. (MAPCARE)

Hospitals participating in the STEPCARE trial may opt to participate in the biomarker substudy if they include >20 patients/year, have the possibility to collect and process samples 24/7. Processing should be done by professional or experienced personnel.

Blood samples will be collected at 12, 24, 48, and 72 hours after randomization in selected sites, aliquoted and frozen on-site. Serum, plasma and PAX-RNA vials are collected. After trial completion, samples will be stored in a central biobank. Sample analysis will be performed in batch after trial completion.

Functional outcome will be assessed at 30 days and 6 months after cardiac arrest. Primary outcome is poor functional outcome (modified Rankin Scale 4-6) at six months. Secondary outcomes are poor functional outcome at 30 days and survival at 6 months.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • From sites participating in the STEPCARE biomarker substudy and withOut-of-hospital cardiac arrest
  • Sustained ROSC - defined as 20 minutes with signs of circulation without the need for chest compressions
  • Unconsciousness defined as not being able to obey verbal commands (FOUR-score motor response of <4) or being intubated and sedated because of agitation after sustained ROSC.
  • Eligible for intensive care without restrictions or limitations
  • Inclusion within 4 hours of ROSC

Exclusion criteria

  • On ECMO prior to randomization
  • Pregnancy
  • Suspected or confirmed intracranial hemorrhage
  • Previously randomized in the STEPCARE trial.

Treatment and study plan

Primary outcomes

  1. Functional outcome according to the modified Rankin Scale

    Time frame: 6 months after randomisation

    Poor functional outcome modified Rankin Scale 4-6 (moderately severe disability, severe disability or death). A higher score indicates a worse score.

Secondary outcomes

  1. Functional outcome according to the modified Rankin Scale

    Time frame: 30 days after randomisation

    Poor functional outcome modified Rankin Scale 4-6 (moderately severe disability, severe disability or death). A higher score indicates a worse score.

  2. Mortality at 6 months

    Time frame: 6 months after randomisation

    Mortality from any cause at six months follow-up

Study contacts

Contact information is provided by the study sponsor or research team.

Marion Moseby-Knappe, MD, PhD

CONTACT

[email protected]

+464671000

Niklas Nielsen, Prof, Principal Investigator

CONTACT

[email protected]

+46424061000

Sponsors and collaborators

Lead sponsor

Region Skane

Other

Collaborators

  • Copenhagen Trial Unit, Center for Clinical Intervention Research
  • Medical Research Institute of New Zealand
  • The George Institute
  • University of Helsinki

Registry information

Important dates

Study start
2023
Primary completion
2027
Study completion
2029
First posted
Jun 24, 2024
Registry last updated
Sep 19, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.